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Abstract
Background: Treatment of Chagas disease, caused by Trypanosoma cruzi, relies on nifurtimox and benznidazole (BZL),
which present side effects in adult patients, and natural resistance in some parasite strains. Hydroxymethylnitrofurazone
(NFOH) is a new drug candidate with demonstrated trypanocidal activity; however, its safety is not known.
Methods: HepG2 cells dose response to NFOH and BZL (5–100 mM) was assessed by measurement of ROS, DNA damage
and survival. Swiss mice were treated with NFOH or BZL for short-term (ST, 21 d) or long-term (LT, 60 d) periods. Sera levels
of cellular injury markers, liver inflammatory and oxidative stress, and fibrotic remodeling were monitored.
Results: HepG2 cells exhibited mild stress, evidenced by increased ROS and DNA damage, in response to NFOH, while BZL
at 100 mM concentration induced .33% cell death in 24 h. In mice, NFOH ST treatment resulted in mild-to-no increase in
the liver injury biomarkers (GOT, GPT), and liver levels of inflammatory (myeloperoxidase, TNF-a), oxidative (lipid peroxides)
and nitrosative (3-nitrotyrosine) stress. These stress responses in NFOH LT treated mice were normalized to control levels.
BZL-treated mice exhibited a .5-fold increase in GOT, GPT and TNF-a (LT) and a 20–40% increase in liver levels of MPO
activity (ST and LT) in comparison with NFOH-treated mice. The liver inflammatory infiltrate was noted in the order of BZL.
vehicle$NFOH and BZL.NFOH$vehicle, respectively, after ST and LT treatments. Liver fibrotic remodeling, identified after
ST treatment, was in the order of BZL.vehicle.NFOH; lipid deposits, indicative of mitochondrial dysfunction and in the
order of NFOH.vehicle.BZL were evidenced after LT treatment.
Conclusions: NFOH induces mild ST hepatotoxicity that is normalized during LT treatment in mice. Our results suggest that
additional studies to determine the efficacy and toxicity of NFOH are warranted.
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Introduction
Chagas disease is endemic in 21 countries, and the World
Health Organization estimates that approximately 9-million
people are infected by Trypanosoma cruzi [1]. The acute phase
lasts for ,2-months, and is characterized by high parasitemia and
fever. Chronic chagasic cardiomyopathy is the most severe clinical
consequence of T. cruzi infection, which is detectable in 30% of
the patients several years after the primary infection [2].
A considerable advancement in the knowledge about the
biology of the T. cruzi parasite has been made in the last few
decades (reviewed in [3]). Yet, treatment of Chagas disease still
relies on two drugs, namely nifurtimox (NFX, Bayer) and
benznidazole (BZL), that were developed during the 1960s and
are currently manufactured and distributed by Roche (Rochagan,
in Brazil), and Maprimed and ELEA laboratories (Abarax) in
Argentina [4]. Since the T. cruzi life cycle involves intracellular
division and subsequent parasite release to peripheral blood, a
long-term treatment period (usually an oral dose for 60 days) is
required. Both drugs are well tolerated by infants and used as
standard treatment to control acute infection by T. cruzi in
children [5]. However, chronic chagasic cardiomyopathy is a
complex malady that involves immune mechanisms as well as
parasite persistence. Several studies have noted that treatment
with BZL or NFX is not always effective in controlling the chronic
disease in chagasic patients. Moreover, these drugs trigger multiple
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side effects in adults, resulting in noncompliance with long-term
treatment [6]. Further, BZL and NFX are not effective against all
naturally occurring T. cruzi strains, and some strains have been
documented to acquire resistance to these drugs [7–9]. Thus,
alternative therapeutic drugs that are well-tolerated, safe, and
effective against T. cruzi are urgently needed.
Due to their limited commercial potential, development of new
drugs for Chagas disease is perhaps not a viable option. Instead,
drug repurposing–finding a new indication for an existing drug—
has enormous potential in developing a new therapy against
parasitic diseases. Nitrofurazone (NF), commercialized as a topical
medicine for bactericidal activity against gram-positive and gram-
negative bacteria, has recently been shown to inhibit trypa-
nothione reductase, the main enzyme responsible for xenobiotic
metabolism in T. cruzi [10]. Subsequently, NF was found to have
significant anti-T. cruzi activity [11]. Unfortunately, NF showed
toxicity against mammalian cells [12] and long-term treatment
with NF induced ovarian cancer in mice and rats [13,14], spurring
the identification of alternative chemicals with specific activity
against T. cruzi only. Among the latter, hydroxymethylnitrofur-
azone (NFOH) was identified as a derivative of NF. The reduction
of nitrofurazone is pH-dependent and in acidic medium the
hydroxylamine derivative, involving four electrons, is the principal
product formed. In aqueous-alkaline medium, the reduction of
nitrofurazone occurs in two steps, the first involving one electron
to form the nitro-radical anion and the second corresponding to
the hydroxylamine derivative formation. NFOH presented the
same voltammetric behavior and electroactivity, indicating that
the molecular modification performed in NF did not change its
capacity to be reduced [15]. We and others have shown NFOH
has 2-fold more cytotoxic activity than the parental compound NF
against T. cruzi [15,16]. The mechanism of action of NFOH
against T. cruzi is not completely clear; however, like all
nitroheterocyclic compounds, it is enzymatically reduced at the
nitro group resulting in the generation of nitroanion (RNO2
N2)
and hydronitroxide (RNHON2) free radicals [17]. NFOH has also
been shown to at least partially interfere with mRNA trans-splicing
[16] and cruzipain activity [18] that are essential for parasite
invasion as well as differentiation to replicative form.
Before NFOH can be tested and promoted further as an anti-T.
cruzi drug for human use, it is essential that we evaluate its safety
profile. In a therapeutic regimen administered to T. cruzi infected
mice, NFOH and BZL provided comparable control of T. cruzi
and survival from infection (84% and 67%, respectively) [11],
while NF caused 75% mortality in infected mice. Accordingly, in
this study, we have evaluated the liver toxicity of NFOH in
comparison with BZL by using in vitro and in vivo models. We
treated HepG2 liver cells and mice with the two drugs and
assessed inflammation, oxidative stress, and cell survival or tissue
remodeling. We chose to treat mice with NFOH for short-term
(ST) and long-term (LT) periods that were similar to the
recommended regimen for the BZL treatment of children and
adults exposed to T. cruzi infection.
Materials and Methods
Ethics statement
All animal experiments were performed according to the
National Institutes of Health Guide for Care and Use of
Experimental Animals and approved by the Ethical Committee
of the National University of Salta and the Animal Care and Use
Committee at the UTMB (protocol # 08-05-029).
Cell, mice and treatment
A hepG2 human hepatocyte cell line was obtained from the
American Tissue Culture Collection (Maryland, USA). The cells
were cultured in complete DMEM high glucose media (Gibco)
supplemented with 10% FBS at 37uC, 5% CO2.
Female Swiss mice were bred at the Instituto de Patologia
Experimental mouse facility. Swiss mice have been widely
employed as animal models for experimental chemotherapy in
Chagas disease [19]. NFOH was kindly provided by Dr. Man
Chin Chung (Faculdade de Ciencias Farmaceuticas, Universidade
Estadual Paulista, Brazil). BZL (Roche Pharmaceuticals, Brazil)
was obtained from the Ministry of Public Health, Province of
Salta, Argentina. Mice (30-day old) received NFOH (150 mg/kg/
day) or BZL (150 mg/kg/day), suspended in 9% NaCl/5%
Tween-80 (vehicle solution), as an oral dose of 100 ml, once a day
(six days per week). The selected doses of the BZL and NFOH
mimicked the dose per kg and dose regime (two months of daily
treatment) of humans. All experiments were carried out in female
mice because they develop disease symptoms similar to those seen
in human infection. Additionally, we have noted that the female
mice exhibited a higher tolerance to infection than did male mice
[11]. One set of mice (n = 9/group) received the treatment for 21
days to allow us to determine the acute (short-term, ST) liver
toxicity of the drugs. Another set of mice (n = 9/group) received
the treatment for 60 days to facilitate our knowledge of the chronic
(long-term, LT) liver toxicity of the drugs. Mice given the vehicle
solution were used as controls. After treatment, mice were
sacrificed, and sera samples and liver tissues stored at 280uC
until use.
Cell survival and proliferation
HepG2 cells were cultured as above, seeded at 7.56104 cells/
well in 96-well microplate, and incubated overnight in complete
media at 37uC, 5% CO2. Cells were treated in serum-free medium
with NFOH or BZL (5, 50 and 100 mM) for 24–48 h. To examine
the drug-induced changes in cell viability and proliferation, after
the drug treatment, we incubated the cells for 30 min in the
presence of AlamarBlue reagent (Life Technologies/Invitrogen,
10% final concentration). Resazurin, the active ingredient of
alamarBlue reagent, is a non-toxic, cell-permeable compound that
is blue in color and virtually non-fluorescent. Upon entering cells,
resazurin is reduced to resorufin, a compound that is red in color
and highly fluorescent. Viable cells continuously convert resazurin
to resorufin, increasing the overall fluorescence and color of the
media surrounding cells. Fluorescence was measured at Ex540/
Em590 nm on a SpectraMax Microplate Reader. Results were
analyzed as per the manufacturer’s instructions.
Author Summary
Hydroxymethylnitrofurazone (NFOH) is a promising drug
candidate with demonstrated trypanocidal activity in
experimental models of Trypanosoma cruzi infection and
chronic disease development. In this study, we monitored
the safety of NFOH in established in vitro and in vivo
models. Our data show that NFOH did not induce
hepatocyte cell death. Short-term or long-term treatment
of mice with NFOH did not induce hepatic stress measured
by cellular injury, inflammation or fibrosis. Benznidazole,
the currently used treatment against acute infection in
humans, was more toxic and induced chronic inflamma-
tion and liver injury in mice. We conclude that NFOH
should be studied further to determine its potential safety
for human use as an anti-parasite therapy.
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Flow cytometry analysis of ROS production and DNA
damage
HepG2 cells were incubated in the presence or absence of NFOH
or BZL for 24 h, as above. For the quantitation of reactive oxygen
species (ROS), 5 mM CellROX Green reagent was added to each
well in complete media, and cells were incubated at 37uC for
30 minutes. CellROX Green is cell-permeant and non-fluorescent,
or very weakly fluorescent, in the reduced state. Upon oxidation, the
reagents exhibit strong fluorescence and remain localized within the
cell. Cells were washed with PBS and analyzed by flow cytometry.
For assessing the effect of NFOH and BZL in inducing DNA
damage, HepG2 cells were treated with NFOH or BZL for 24 h,
as above. Cells were harvested, washed with PBS, fixed with 3.7%
paraformaldehyde for 15 min at 4uC, and permeabilized with
90% methanol. Cells were then incubated at room temperature
for 2 h with mouse anti-8-oxo-dG antibody (250-fold dilution,
EMD Milipore, Billerica, MA) and for 30 min with PE-conjugat-
ed, anti-mouse IgG (eBioscience, San Diego, CA). Cells stained
with isotype-matched IgGs were used as controls. Samples were
visualized on an LSRII Fortessa Cell Analyzer, acquiring 30–
50,000 events in a live cell gate, and further analysis performed by
using FlowJo software (version 7.6.5, Tree-Star, San Carlo, CA).
Tissue homogenates
Frozen liver tissues (25 mg) were homogenized in 0.5 ml of ice-
cold lysis buffer (25 mM Tris pH 7.6, 150 mM NaCl, 1% sodium
deoxycholate, 1% Igepal CA-630, 0.1% SDS, 10 ml/ml sodium
orthovanadate, 10 mM PMSF and 10 ml/ml Sigma protease
inhibitor cocktail), and centrifuged at 3000 g for 10 min at 4uC.
Supernatants were stored at 280uC, and protein concentration
determined by the Bradford method.
Cellular injury markers
The activities of glutamate oxaloacetate transaminase (GOT) and
glutamate pyruvate transaminase (GPT), alternatively called aspar-
tate transaminase (AST) and alanine transaminase (ALT), respec-
tively, were determined by using commercially available assay kits
(Wiener Lab, Rosario, Argentina). Briefly, for the GOT/AST assay,
50 ml of sera sample or liver homogenate (,100-mg protein) was
added to reagent A containing 12 mM 2-oxoglutarate, 0.18 mM
NADH, 420 U/l malate dehydrogenase (MDH), and 600 U/l
lactate dehydrogenase (LDH). The reaction was started by adding
80 mM Tris HCl buffer, pH 7.8, containing 240 mM L-aspartate,
and the resultant oxaloacetate formation coupled with NADH
oxidation by MDHmonitored at 340 nm. For the GPT/ALT assay,
50 ml of sample was added to reagent A containing NADH, 2-
oxoglutarate (as above) and 1200 U/l LDH. The reaction was started
by adding 80 mM Tris HCl buffer, pH 7.8, containing 500 mM L-
alanine, and resultant reduction of pyruvate coupled with NADH
oxidation by LDH monitored at 340 nm (e=6,220 M21cm21).
Oxidative/nitrosative stress
We measured lipid peroxides, a biomarker of oxidative stress
[20], by using a LPO Assay Kit (Cayman). Briefly, liver
homogenate LPOs were extracted into chloroform, mixed with
methanol (1:1, v/v), and added in triplicate (55 ml/well) to 96-well
plates. The reaction was started with addition of 50 ml/well of
4.5 mM FeSO4/0.2 M HCl, 3% ammonium thiocyanate (chro-
mogen) solution. The redox reaction with ferrous ions was stopped
after 5 min, and absorbance monitored at 500 nm (standard
curve: 0–500 mM 13-hydroperoxy octadecadienoic acid).
The level of protein nitrosylation, an indicator of nitrosative stress,
was determined by Western blotting [21]. Tissue homogenates
(10-mg protein) were resolved on 10% SDS polyacrylamide gels, and
transferred to PVDF membranes by using a vertical Criterion
Blotter (Bio-Rad). Membranes were washed in TBS (20.4 mM Tris,
150 mM NaCl, pH 7.6), blocked for 1 h in 5% nonfat milk (NFM),
and incubated overnight at 4uC with anti-3-nitrotirosine antibody
(clone 2A8.2, 1:2000, Millipore). After washing with TBS-T (TBS/
0.1% Tween-80), membranes were incubated for 1 h at room
temperature with HRP-conjugated secondary antibody (1:10,000,
Southern Biotech), and signal was developed with an enhanced
chemiluminiscence detection system (GE-Healthcare). Membranes
were incubated in stripping buffer (Thermo Scientific) and probed
with anti-b-actin antibody (1:10,000, Sigma) to confirm an equal
loading of samples. All antibody dilutions were made in NFM. Spot
densitometry for protein bands was carried out using a FluorChem
HD2 Image Analyzer (Alpha Innotech).
Myeloperoxidase
MPO activity was determined as a biomarker of macrophage/
neutrophil activation [20]. Liver homogenates (10 mg protein) were
added in triplicate to 0.53 mM o-dianisidine dihydrochloride and
0.15 mM H2O2 in 50 mM KH2PO4/K2HPO4 buffer (pH 6.0).
After incubation for 5 min at room temperature, the reaction was
stopped with 30% sodium azide, and the change in absorbance was
measured at 460 nm. Sample protein content was measured by the
Bradford Method, and 1 unit MPO was defined as that degrading 1
n mol H2O2/min at 25uC (e=11300 M
21.cm21).
Cytokine levels
TNF-a levels were measured as a molecular marker of
inflammation. Total RNA was isolated from frozen tissue sections
by using the RNeasy plus Kit (Qiagen), and analyzed for quality and
quantity on a SpectraMax UV microplate reader. After reverse
transcription of 2 mg RNA with poly(dT)18, first-strand cDNA was
used as a template in a real-time PCR on an iCycler Thermal Cycler
with SYBR-Green Supermix (Bio-Rad) and specific oligonucleotides
for TNF-a (59-GTT CTA TGG CCC AGA CCC TCA CA-39 and
59-TAC CAG GGT TTG ACC TCA GC-39) and GAPDH (59-
TGG CAA AGTGGA GAT TGT TG-39 and 59-TTC AGC TCT
GGGATGACCTT-39). The PCR Base Line Subtracted Curve Fit
mode was applied for Threshold Cycle (Ct) and mRNA level
measured by iCycler iQ Real-Time Detection Software (Bio-Rad).
The threshold cycle (Ct) values for target mRNA were normalized to
GAPDH mRNA, and the relative expression level of TNF-a gene
was calculated with the formula n-fold change=22DCt, where DCt
represents Ct (TNF-a)2Ct (GAPDH) [22].
Tissue homogenates were also subjected to measurement of
TNF-a cytokine by using an optEIA ELISA kit (Pharmingen, San
Diego, CA).
Histology
Liver tissues were fixed in formalin, embedded in paraffin, and
5-mm sections were stained with hematoxylin and eosin (H&E) and
Masson’s Trichrome to examine inflammatory infiltrates and
collagen deposition, respectively. Cryostat tissue-sections (fixed in
OCT cryostat-embedding medium, TissueTek) were stained with
Oil red O to examine lipid/fat deposition.
In general, we analyzed each tissue section for .10-microscopic
fields (1006 magnification), and examined three different tissue
sections/mouse (n = 3–4 mice/group) to obtain a semi-quantita-
tive score. Presence of inflammatory cells was scored as I (absent),
II (focal or mild, 0–1 foci), III (moderate, $2 foci), IV (extensive
inflammatory foci, minimal necrosis, and retention of tissue
integrity), and V (diffused inflammation with severe tissue necrosis,
interstitial edema, and loss of integrity). Inflammatory infiltrates
Toxicity of Anti-parasite Drugs
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were characterized as diffused or focal depending upon how
closely the inflammatory cells were associated. Fibrosis and lipid
deposition were assessed by measuring the Masson’s Trichrome-
stained collagen area (blue) and Oil Red O-stained intrahepato-
cyte lipid area (red), respectively, as a percentage of the total area
by using Simple PCI software (version 6.0; Compix, Sewickley,
PA) connected to an Olympus polarizing microscope system
(Center Valley, PA). All pixels with blue stain in Masson’s
trichrome-stained sections and red stain in Oil Red O were
selected to build a binary image, and utilized for calculating the
percentage of the area occupied by collagen and lipid droplets,
respectively. The fibrotic area was further scored as I (,10% of
total area), II–III (10–30% of total area), III–IV (30–60% of total
area) and V (.60% of total area). Oil red O (intrahepatocyte lipid
deposition) was scored as I (absent), II (,10% of total area or
patchy distribution of tiny red droplets), III (10–30% of total area
or scattered tiny red droplets), and IV (.30% of total area or
intense red staining of variable size droplets) [23].
Data analysis
Data (mean 6 SD) were derived from at least triplicate
observations per sample (n = 9–12 animals/group), confirmed to
be normally distributed by a Q-Q test and histogram plot, and
analyzed by Student’s t test (comparison of two-groups) and 1-way
analysis of variance (ANOVA) with a Holm-Sidak test (comparison
of multiple groups). Non-parametric Kruskal-Wallis Dunn’s test
was used to analyze the statistical significance for each cytokine’s
gene expression. The level of significance is presented by * (normal
versus treated; *p,0.05, **p,0.01).
Results
In vitro cytotoxicity of NFOH in HepG2 cells
We first evaluated the dose response of the HepG2 cell line to
NFOH and BZL. Hepatocytes express cytochrome P450 isoforms,
including Cyp2E1 that elicit ROS generation under stress
conditions. Additionally, impairment of mitochondrial permeabil-
Figure 1. Hepatocytes dose response to NFOH and BZL. HepG2 cells (7.56104/well) were incubated in presence of 5–100 mM NFOH or BZL for
24 h. Cells incubated with vehicle solution (10% DMSO) were used as controls. Shown are flow cytometry evaluations of (A) CellROX Green oxidation
by intracellular ROS and (B) 8-oxo-dG levels as an indicator of DNA damage. The mean fluorescence intensity (MFI) of CellROX (A.a) and 8-oxo-dG
(B.a) as an indicator of the extent of ROS production and DNA damage, respectively; and the mean percentage of CellROX+ (A.b) and 8-oxo-dG+
(B.b) cells was determined. (C) HepG2 cells were incubated with 5–100 mM NFOH or BZL as above. Cell survival was determined at 24 h (C.a) and
48 h (C.b) post-treatment by an AlamarBlue assay. Data are presented as mean 6 S.D. and derived from two independent experiments (triplicate
observations per treatment per experiment). Significance is shown as *p,0.05, **p,0.01, ***p,0.001 (vehicle control-versus-treated).
doi:10.1371/journal.pntd.0003231.g001
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ity transition, fatty acid b-oxidation, and inhibition of mitochon-
drial respiration are all potential mechanisms of ROS generation
under stress conditions. We noted a 40–75% increase in CellRox
fluorescence (detects intracellular ROS, (Fig. 1A.a) in 27–72%
(Fig. 1A.b) of the HepG2 cells treated with 5–100 mM NFOH.
The maximal increase in ROS generation was observed when
HepG2 cells were treated with 50 mM NFOH treatment. The 8-
oxo-29-deoxyguanosine(8-oxo-dG) is the major product of DNA
damage and concentrations of 8-oxo-dG within a cell are used as a
measurement of oxidative stress. We noted an up to 33% increase
in 8-oxo-dG levels (Fig. 1B.a) in 23% (Fig. 1B.b) of the HepG2
cells treated with increasing concentrations of NFOH. Despite the
increase in ROS and DNA damage biomarkers, cell viability,
measured by AlamarBlue assay, was not significantly altered by
NFOH treatment for 24 h (Fig. 1C.a) or 48 h (Fig. 1C.b). In
comparison, HepG2 cells treated with increasing concentrations of
BZL showed no statistically significant increase in ROS generation
and DNA damage (Fig. 1A&B); however, a cytotoxic response to
increasing concentrations of BZL was noted (Fig. 1C). The
maximal cytotoxicity (33% cell death) was observed when cells
were treated with 100 mM BZL for 24 h (Fig. 1C.a) or 48 h
(Fig. 1C.b). Together, these data suggest that NFOH (5–100 mM)
induces a mild stress response in hepatopcytes, while BZL at
100 mM concentrations is cytotoxic and causes cell death.
NFOH does not cause short- or long-term liver toxicity in
mice
We used a well-established experimental model of Swiss mice
for assessing the in vivo cytotoxicity properties of NFOH. We have
previously demonstrated NFOH activity against T. cruzi in Swiss
mice [11]. These outbred mice display a broader response to drugs
than is observed in in-bred C3H/HeN, C57BL/6 and Balb/c
mice [19].
We measured elevation in GOT and GPT activities as a general
biochemical marker of liver injury after 21 d (ST) and 60 d (LT)
treatment with NFOH (controls: vehicle solution). We observed no
significant difference in GOT and GPT activities in the sera of
mice treated with NFOH or vehicle for the ST and LT period
(Fig. 2B&C). Likewise, liver levels of GOT and GPT activities in
mice treated with NFOH or vehicle for ST and LT were not
Figure 2. (A) Experimental design for the toxicity studies in mice. Mice received an oral dose of 150 mg/kg/day of NFOH, BZL or the vehicle
(9% NaCl - 5%Tween-80) once a day for 6 days per week. Mice were treated for 21 or 60 days to determine the toxicity of short-term (ST) and long-
term (LT) treatment, respectively. (B–D) Liver toxicity of anti-parasite drugs. Glutamate oxaloacetate transaminase (B&D) and glutamate
pyruvate transaminase (C&E) activities in mice sera (B&C) and liver homogenates (D&E) after ST and LT treatment with NFOH and BZL were
determined as an indicator of liver injury. Mice treated with vehicle only were used as controls. Data in figures 2–7 are presented as mean6 S.D. (n$
9 mice per group, triplicate observations per mouse). Significance is shown as *p,0.05, **p,0.01, ***p,0.001 (vehicle control-versus-treated).
doi:10.1371/journal.pntd.0003231.g002
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statistically different, and comparable to those noted in normal
controls (Fig. 2D&E). In comparison, mice treated with BZL for
LT exhibited a.5-fold (p,0.05) increase in the sera levels of GPT
activity and liver levels of GOT activity (Fig. 2C&D). These data
suggest that NFOH is not hepatotoxic, and its treatment for ST or
LT is safe. In comparison, LT treatment with BZL was
hepatotoxic and caused chronic cellular injury.
Phagocyte activation and oxidative damage in response
to NFOH
The host defense response to NFOH or BZL can result in
activation of macrophages and neutrophils that produce oxidative
burst, nitric oxide (NNO), and HOCl supported by induction of
NADPH oxidase, inducible nitric oxide synthase (iNOS) [23–25],
and MPO [26], respectively. The cytotoxicity of reactive oxygen
species (ROS) results in oxidation of cell constituents, including
proteins, lipids, and DNA, which lead to deterioration of cellular
structure and function. Additionally, NNO reacts with O2
N2 and
forms peroxynitrite (ONOO2) and peroxynitrous acid (ONOOH)
that cause increased protein 3-nirotyrosine (3NT) formation
[20,23,27].
We investigated host defense responses to NFOH and BZL by
measurement of MPO activity and oxidative/nitrosative stress.
The level of MPO activity in liver homogenates of mice treated
with NFOH for ST or LT was not statistically different when
compared to that noted in mice given vehicle only, and was within
the basal-level range (100–150 milli-units/mg protein). The BZL-
treated mice exhibited a 20–40% increase in liver level of MPO
activity when compared to that noted in NFOH-treated mice
(Fig. 3A). LPO refers to highly reactive hydroperoxides of
saturated and unsaturated lipids, formed by oxidation [28].
NFOH and BZL treatment for ST or LT resulted in no significant
increase in the liver levels of LPO formation in comparison to
those in control mice treated with vehicle solution (Fig. 3B). The
basal level of LPO (,0.25 n mol/mg protein) in all mice,
irrespective of ST or LT treatment with NFOH, BZL or vehicle
was within the lowest detection range. The polypeptide-bound 3-
NT residues, formed by peroxynitrite attack, were monitored by
Western blotting. These data showed that the 3-NT level in liver
homogenates of mice given ST NFOH or BZL treatment was
increased by,2.5-fold when compared to those in normal controls,
and were similar to those noted in mice given vehicle only
(Fig. 3C&D). The 3-NT contents normalized to b-actin were
unchanged after LT exposure to NFOH, BZL, or vehicle in treated
mice (Fig. 3C&D). Overall, the data presented in Fig. 3 suggested
that treatment of mice with NFOH or BZL caused a short-term
increase in nitrosative stress that was likely a placebo effect, and, in
general, both anti-parasitic drugs did not elicit long-term liver injury
by phagocyte activation and oxidative damage in mice.
NFOH does not cause chronic liver inflammation
Next, we determined the effects of NFOH and BZL treatment
on liver inflammation. Mice treated with NFOH, BZL or vehicle
for ST exhibited a 13–15-fold increase in TNF-a mRNA
expression when compared to that noted in normal (untreated)
controls (Fig. 4A). The increase in TNF-a expression was also
reflected by increased levels of TNF-a protein in liver homoge-
nates of mice treated with NFOH, BZL or vehicle only for ST
(range: 58–74-pg/mg protein, Fig. 4B). When given for LT, the
NFOH-induced increase in TNF-a mRNA and protein level was
decreased by .4-fold, when compared to that noted after ST
NFOH treatment and similar to that noted in controls
(Fig. 4A&B). Mice given BZL treatment for LT exhibited a 2-
fold decline in TNF-a mRNA and a 30% increase in TNF-a
protein level when compared to that noted after ST BZL
treatment (Fig. 4A&B).
Histological studies showed that ST treatment with NFOH and
BZL resulted in a mild increase in liver inflammatory infiltrate,
extensive inflammatory lesions (histological score: II–III) being
detected in BZL-treated mice followed by vehicle- and NFOH-
treated mice (Fig. 5A.a,c,e & 4B). Upon LT treatment, liver
inflammatory lesions were noted to be in the order of BZL.
NFOH $ vehicle. Focal lesions with 0–2 inflammatory foci per
Figure 3. NFOH causes short-term phagocytic activation and oxidative damage. Mice were treated with NFOH and BZL as in Fig. 1, and
liver tissue homogenates were prepared. (A) Myeloperoxidase activity was measured as a biomarker of phagocyte activation. (B) Lipid
hydroperoxides levels were evaluated as a marker of oxidative stress. (C&D) Liver homogenates were subjected to Western blotting (C) with anti-3-
nitrotyrosine antibody (Control: anti-b-actin antibody). Densitometry quantitation of 3-NT band intensity, normalized to b-actin, is presented in panel D.
doi:10.1371/journal.pntd.0003231.g003
Toxicity of Anti-parasite Drugs
PLOS Neglected Tropical Diseases | www.plosntds.org 6 October 2014 | Volume 8 | Issue 10 | e3231
microscopic field (histological score: II–IV) were primarily noted in
the livers of mice after LT treatment with NFOH or vehicle
solution (Fig. 5A.b,d & 5B). The LT treatment with BZL resulted
in widespread inflammation in liver, evidenced by finding of .4-
inflammatory foci/mf, extensive and diffused inflammation
associated with severe tissue necrosis, interstitial edema, and loss
of integrity (histological score: III–V, Fig. 5A.f & 4B). Overall, the
data presented in Figs. 4&5 suggested to us that NFOH, BZL and
vehicle caused a short-term increase in liver levels of TNF-a and
inflammatory infiltrate that was likely a placebo effect. When used
for LT, NFOH was well-tolerated, while LT treatment with BZL
resulted in extensive tissue inflammation in mice.
Liver remodeling and lipid deposition in response to
NFOH
ROS and inflammatory mediators have been suggested to
promote tissue remodeling and dysfunction through diverse
mechanisms [23,29]. We performed histological staining of the
liver tissue sections with Masson’s Trichrome and oil red O,
respectively, for the detection of collagen (Fig. 6) and lipid droplets
(Fig. 7). Our data showed the ST with NFOH resulted in a mild
degree of collagen deposition in ,10% of the tissue area
(histological score: II, Fig. 6A.b & 6B, p,0.01) that was
significantly lower than that noted in mice given vehicle or BZL
treatment. The BZL-treated mice exhibited an up to 30% fibrotic
area (histological score: II–III) in liver tissue (Fig. 6A.c & 6B). Very
few collagen lesions (,10% fibrosis, histological score: 0–I)
indicative of liver remodeling were noted after LT treatment with
NFOH, BZL or vehicle solution (Fig. 6A.d–f & 6B).
The extent of lipid deposition, an indicator of mitochondrial
dysfunction, was not significantly different after ST treatment with
NFOH, BZL or vehicle (Fig. 7A.a–c & 7B). LT treatment with
NFOH and BZL resulted in extensive and uniformly scattered
lipid droplets of variable size in the liver tissue of mice (20–35% of
total area; histological score III–IV) than was noted in vehicle-
treated mice (Fig. 7A.d–f & 7B, p,0.01). The extent of lipid
deposition appeared to be high in NFOH-treated mice. Together,
the results presented in Figs. 6&7 suggest that BZL resulted in
mild-moderate acute remodeling of the liver that was replaced by
extensive lipid deposition after LT treatment. In comparison, ST
treatment with NFOH was not pro-fibrotic, and long-term
treatment with NFOH resulted in minimal remodeling and a
degree of metabolic dysfunction in the liver of treated mice.
Discussion
BZL and NFX, drugs that provide the only line of therapy
against acute T. cruzi infection, were released to the market
without extensive testing for possible adverse effects, which have
Figure 4. Liver inflammatory cytokine response to treatment with anti-parasite drugs. Liver tissues were harvested after ST and LT
treatment with NFOH, BZL, and vehicle, as detailed in Fig. 1. (A) Shown are the relative changes in gene expression for TNF-a, determined by real
time RT-PCR. Results were normalized to GAPDH mRNA. (B) TNF-a levels in tissue homogenates were determined by an ELISA.
doi:10.1371/journal.pntd.0003231.g004
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been reported over the four decades that these drugs have been in
use. It was confirmed that NFX has more severe secondary effects
than does BZL; these range from alterations of the cellular
immune responses [30], peripheral nervous system toxicity, and
testicular and ovarian damage to mutagenic effects [17,31–34]. In
clinical practice, it is recommended to interrupt anti-T. cruzi
treatment when the adverse effects of BZL are detected in adult
patients [35]. In contrast, children and newborns show a better
tolerance to BZL [36,37].
Different strategies with the overall aim of finding a cure for
Chagas disease are currently under investigation. The major
challenges to testing and implementation of therapeutic use of the
currently available drugs (BZL and NFX) include the resistance of
many of the naturally occurring parasite isolates (e.g. Colombiana)
[9] and low efficacy of treatment during indeterminate and
chronic phase of disease [6–9]. Moreover, additional challenges
are faced in immuno-suppressed chagasic patients that become
recipients of transplanted organs or are HIV co-infected. The
immuno-suppressed patients present a short window of time when
they should be treated with anti-parasite drugs. Otherwise,
parasite recurrence results in severe acute infection and organ
failure. Due to high toxicity concerns, BZL and NFX are not
always recommended for treatment of immuno-suppressed
patients [38]. In this scenario, NFOH has emerged as a promising
compound for its anti-T. cruzi activity, both in vitro and in vivo,
and its favorable pharmacological properties [39,40]. NFOH,
derived from hydroxymethyl substitution at the primary amide of
nitrofurazone [15], also has a higher solubility in water than does
NF and BZL, which likely would facilitate its oral administration.
In a murine model of acute T. cruzi infection, NFOH was highly
effective in controlling parasitemia evidenced by the observation
that infected mice, after NFOH treatment, exhibited no signal for
parasite DNA by a highly sensitive PCR approach, and sero-
converted with depletion of anti-parasite antibodies [11].
NFOH is a derivative of nitrofurazone (NF). NF is highly toxic
and shown to result in single strand DNA breaks [41] and
oxidative DNA damage [42], and is considered to be potentially
carcinogenic [13]. Considering the high toxicity of NF, it is
important to evaluate the toxicity of NFOH in vitro and in vivo
before it is recommended for treatment of T. cruzi infection in
Figure 5. NFOH does not cause chronic liver inflammation. Paraffin-embedded liver tissue sections (5 mm) were submitted to H&E staining
(blue: nuclear, pink: muscle/cytoplasm). (A) Shown are the representative images (magnification: 406) of liver tissue-sections from mice treated with
vehicle (a&b), NFOH (c&d), and BZL (e&f) for short-term (a,c,e) and long-term (b,d,f). (B) Inflammatory infiltrate in liver tissue sections (3-sections/
mouse, n.3/group) was scored as described in Materials and Methods.
doi:10.1371/journal.pntd.0003231.g005
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humans. Accordingly, the present study was designed to examine
the adverse effects of NFOH treatment in HepG2 cells and ST and
LT treatment of NFOH in mice. We focused on examining the
effects of NFOH on hepatocytes and liver because the liver is the
main detoxifying organ in mammals. Metabolism of xenobiotics in
the liver involves phase I and phase II reactions that add hydroxyl
and methyl groups, respectively, to a given compound. NFOH is a
nitrofurazone with an N-hydroxymethylation at the primary amide
and was anticipated to cause significantly reduced toxicity [11].
Our in vitro studies evaluating the dose response of HepG2 cells
clearly demonstrated that NFOH at higher concentrations (50–
100 mM) induced mild stress as was evidenced by the observation
of ROS production and DNA damage (Fig. 1A&B). However, the
NFOH-induced stress was controlled as we observed no cell death
in NFOH-treated HepG2 cells. Under similar conditions, cyto-
toxicity of BZL was evidenced by induction of cell death in 33% of
the cells (Fig. 1C). Others have shown the nifurtimox and BZL
inhibited DNA and protein synthesis in hepatocytes [43]. In
murine studies, the selected doses for toxicity evaluation were the
same as those that we have previously tested in mouse models of
acute and chronic T. cruzi infection. We included mice treated
with BZL and vehicle (NaCl/Tween-80) as controls. Our data
showed a moderate increase in sera levels of GOT and GPT
(Fig. 1) after ST and LT treatment with NFOH that was similar to
that noted in mice treated with vehicle only. Further, MPO
activity and LPO production, measured as markers of neutrophil
Figure 6. Liver remodeling in response to NFOH treatment. Mice were treated with vehicle solution (a&d), NFOH (b&e) or BZL (c&f) for a short-
term (a,b,c) and long-term (d,e,f). (A) Representative micrographs of liver tissue-sections stained with Masson’s Trichome (magnification: 4006, scale
bar: 100 mm) are shown. (B) Tissue sections (3-sections/mouse, n.3/group) were scored for fibrosis as described in Materials and Methods.
doi:10.1371/journal.pntd.0003231.g006
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activation and macrophage oxidative burst, were present at the
lowest limits of detection in all mice given NFOH or vehicle
throughout the treatment schedule (Fig. 3A&B). These data, along
with the observation of no significant change in TNFa mRNA and
protein level (Fig. 4) suggested to us that NFOH did not induce
hepatic stress associated with cellular injury, oxidative stress, and
innate immune cell activation in vitro or in vivo after ST or LT
treatment. Our observation of a .5-fold increase in hepatic levels
of MPO activity and TNF-a expression in the livers of mice within
3 d after a single dose treatment with 2,3,7,8-tetrachlorodibenzo-
p-dioxin (TCDD, 20-mg/Kg/100 ml peanut oil) in other studies
suggest that when compared with TCDD effects, NFOH has no
acute liver toxicity. The notion of NFOH being liver-safe is also
supported by the observation of a higher degree of GOT release
(5-fold), MPO activity (20–40%), and TNF-a protein levels (up to
20%) in BZL-treated mice in this study (Figs. 2–4). Others have
also shown the BZL toxicity by alterations in mitochondrial
function in liver of treated rats [44].
We corroborated the biochemical findings (Figs. 1–4) of NFOH
safety by histological observations of tissue inflammatory infiltrate,
fibrosis, and lipid deposition in the livers of mice treated for ST or
LT with NFOH, and compared the findings with BZL-treated
Figure 7. NFOH does not cause metabolic stress. Mice were treated for ST (a,b,c) and LT (d,e,f) with vehicle solution (a&d), NFOH (b&e) or BZL
(c&f). (A) Liver deposition of lipids, an indicator of metabolic dysfunction, was determined by Oil Red O staining. Shown are the representative
micrographs (magnification: 6006). (B) Tissue sections (3-sections/mouse, n.3/group) were scored for lipid deposition, as described in Materials and
Methods.
doi:10.1371/journal.pntd.0003231.g007
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mice (Figs. 5–7). NFOH-treated mice consistently exhibited none-
to-low levels of inflammatory infiltrate and fibrotic lesions in liver
tissue sections that were similar to or lower than was noted in
vehicle-treated mice (Figs. 5–7). The extent of liver inflammatory
infiltrate was significantly higher in BZL-treated mice, especially
after LT treatment (Figs. 5). Likewise, BZL-treated mice exhibited
an acute liver fibrosis (Fig. 6) similar to what we have noted in
TCDD-treated mice (unpublished data). The extent of lipid
deposition in liver tissue after LT treatment with BZL and NFOH
was comparable to lipid deposits provoked within three days after
treatment with a single dose of TCDD. Though not withdrawn
from market, BZL has been demonstrated to be more toxic than
NFOH with regard to elicitation of liver inflammatory responses,
fibrosis, and a cellular dysfunction at mitochondrial level, both in
our data presented in this study and other published reports
[17,33]. We surmise that NFOH only causes a mild transient
hepatic injury similar to that caused by vehicle treatment only in
mice. Our results encourage further research on carcinogenicity,
and mechanism of action of NFOH to address its potential safety
for human use as an anti-parasite therapy.
In conclusion, our results showed that ST and LT treatment
with NFOH elicited similar or lower levels of liver oxidative stress,
inflammation and tissue remodeling responses, when compared to
that noted by a similar regimen of treatment with vehicle only. In
comparison, BZL that has been used for the treatment of human
chagasic patients was more toxic and induced chronic inflamma-
tion and liver injury. Our data provide the impetus for future
studies focusing on further characterization of anti-parasite
efficacy, toxicity, and carcinogenicity of NFOH, aiming to
determine its potential safety to be considered as a drug candidate
for the treatment of Chagas disease.
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